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Abstract Menstrually related migraine (MRM) is a par-
ticularly difﬁcult-to-treat pain condition, associated with
substantial disability. Aim of this study was to compare the
efﬁcacy and safety of frovatriptan and zolmitriptan in the
treatment of MRM attacks, analyzing data from a multi-
center, randomized, double blind, cross-over study. We
analyzed the subset of 76 regularly menstruating women
who participated in one head-to-head multicenter, ran-
domized, double blind, cross-over clinical trial and who
took the study drugs to treat MRM attacks. In a randomized
sequence, each patient received frovatriptan 2.5 mg or
zolmitriptan 2.5 mg: after treating three episodes of
migraine in no more than 3 months with the ﬁrst treatment,
the patient had to switch to the other treatment. MRM was
deﬁned according to the criteria listed in the Appendix of
the last Classiﬁcation of Headache disorders of the Inter-
national Headache Society. A total of 73 attacks, classiﬁed
as MRM, were treated with frovatriptan and 65 with
zolmitriptan. Rate of pain relief at 2 h was 52% for
frovatriptan and 53% for zolmitriptan (p = NS), while rate
of pain free at 2 h was 22 and 26% (p = NS), respectively.
At 24 h, 74 and 83% of frovatriptan-treated and 69 and
82% of zolmitriptan-treated patients were pain free and had
pain relief, respectively (p = NS). Recurrence at 24 h was
signiﬁcantly (p\0.05) lower with frovatriptan (15 vs.
22% zolmitriptan). Frovatriptan proved to be effective in
the immediate treatment of MRM attacks, similarly to
zolmitriptan, but showed lower recurrence rates, and thus a
better sustained relief.
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Introduction
Migraine is a particularly frequent disease in women of
fertile age, in whom it usually occurs in the perimenstrual
period [1]. Menstrually related migraine (MRM) is associ-
ated with substantial disability and attacks are more severe,
longer in duration, and have a poorer response to analgesics
than non-menstrual ones [2]. Drug prophylaxis may be
useful for menstrual migraine [3]. However, since this type
of migraine is characterized by relatively low attack fre-
quency, acute treatment may be more indicated [4].
Triptans proved to be the most effective speciﬁc acute
antimigraine medications and are preferable for MRM
treatment in view of its difﬁcult-to-treat nature [4, 5].
Prospective, randomized, controlled trials as well as ret-
rospective analyses and open label studies support the use
of triptans as acute therapy for menstrual migraine [5].
Sumatriptan has been shown to be well tolerated and
effective in providing pain relief in MRM when adminis-
tered in the mild pain phase, also in combination with
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zolmitriptan [13–15], naratriptan [16], rizatriptan [17–21]
and more recently almotriptan [14, 22] and frovatriptan
[23] have been also successfully tested, their different
pharmacokinetic and pharmacodynamic features as respect
to sumatriptan potentially rendering them particularly
suitable for treating menstrual migraine. Recent guidelines
now recommend sumatriptan 50 and 100 mg or rizatriptan
10 mg for acute treatment of MRM, and frovatriptan
2.5 mg or naratriptan 1 mg twice daily for preventive
treatment of this condition [4, 24].
Though there is presently strong evidence of the pre-
ventive efﬁcacy of frovatriptan [25–28], there is less
information on its efﬁcacy in treating acute MRM attacks
of menstrual migraine. In addition, there are presently no
head-to-head studies comparing efﬁcacy of frovatriptan
with that of another second generation triptan in menstrual
migraineurs.
In order to ﬁll this gap we planned an analysis of a
subgroup of MRM sufferers who participated in a recently
published head-to-head multicenter, randomized, double
blind, cross-over clinical trial comparing the efﬁcacy of
frovatriptan versus zolmitriptan [29]. Results of such a
subgroup analysis are reported in the present paper.
Methods
Study population
The main study foresaw inclusion of subjects of both gen-
ders, aged 18–65 years, with a current history of migraine
with or without aura, according to International Headache
Society (IHS) 2004 criteria, and with at least one, but no
more than sixmigraine attacks per month for 6 months prior
to entering the study [29, 30]. Details of study design,
including exclusion criteria, are available from the main
study publication [29]. In the present analysis women with
MRM were selected. This condition was deﬁned according
to IHS criteria as migraine without aura attacks in a men-
struating woman, occurring on day 1 ± 2 (namely days -2
to ?3) of menstruation in at least two out of three menstrual
cycles and additionally at other times of the cycle [30].
Study design
The study design has been extensively reported in a pre-
vious publication [29]. Brieﬂy, this was a multicenter,
randomized, double blind, cross-over study, including 14
Italian centers (see Appendix). Each patient received
frovatriptan 2.5 mg or zolmitriptan 2.5 mg in a randomized
sequence: after treating three episodes of migraine in no
more than 3 months with the ﬁrst treatment, the patient had
to switch to the other treatment. Subjects were encouraged
to treat one to three attacks for a maximum period of
6 months and to visit the center three times. Subjects
having no migraine episodes during one of the two
observation periods were excluded from the study.
Data analysis
This analysis was carried out in all normally menstruating
women randomized to any of the two treatment sequen-
ces, having not positively refused to receive either study
treatment and having treated at least one episode of
menstrual migraine with both medications (intention-to-
treat population).
Study endpoints were (1) the number of pain-relief
episodes at 2 and 24 h; (2) the decrease in migraine
intensity from severe or moderate to mild or none at 2 and
24 h; (3) the number of pain-free episodes at 2 and 24 h
(absence of migraine episodes at 2 and 24 h after intake of
one dose of study drug ± rescue medication]; (4) recur-
rence, deﬁned as an episode of migraine occurring 24 h
after the previous episode, with a migraine-free period
between the two attacks.
Analysis of pain-free episodes was carried out also
according to baseline headache intensity (mild, moderate
or severe). Frequency of pain-free and pain-relief episodes
was also assessed and compared between MRM and non-
MRM attacks.
Continuous variables were summarized by computing
average values and standard deviation (SD), while cate-
gorical variables by computing the absolute value and the
frequency (as percentage). Endpoints were compared
between groups by generalized estimating equation analy-
sis. Kaplan–Meyer curves for cumulative hazard of recur-
rence over the 48 h were also drawn. P value refers to the
statistical signiﬁcance of between-treatment difference.
The level of statistical signiﬁcance was kept at 0.05
throughout the whole study.
Results
The main study population consisted of 107 subjects, of
which 85 women [29]. Overall 76 out of the 85 women had
a regular menstrual cycle and were thus included in this
analysis.
Average subjects’ age was 34 ± 8 years, age at onset of
migraine was 17 ± 5 years, proportion of migraine attack
duration[2 days was 20% and average MIDAS score was
22 ± 18. No statistically signiﬁcant differences were
observed between the main study and MRM subgroup
population.
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A total of 73 attacks (32% of all attacks) classiﬁed as
MRM were treated with frovatriptan and 65 (30%) with
zolmitriptan.
Rate of pain-relief episodes at 2 h was similar (p = NS)
between frovatriptan (52%) and zolmitriptan (53%). The
same ﬁgure applied to the rate of pain relief at 24 h (83%
frovatriptan vs. 82% zolmitriptan, p = NS). Also the rate
of pain-free episodes at 2 and 24 h did not differ between
the two treatment groups (22 and 74% frovatriptan vs. 26
and 69% zolmitriptan; p = NS for both) (Table 1).
Conversely, the risk of recurrence over the 24 h was
signiﬁcantly (p\0.05) lower under frovatriptan than
under zolmitriptan (15 vs. 22%). This was the case also
when recurrence was expressed as cumulative hazard ratio
over the observation period (Fig. 1).
Efﬁcacy of study drugs according to baseline
migraine intensity
Most of the treated attacks had a baseline moderate or
severe intensity. In these attacks the rates of pain free at 2
or 24 h were slightly larger in frovatriptan- than in
zolmitriptan-treated patients, especially at 2 h (Table 2).
MRM and non-MRM attacks
Table 3 shows the number and proportion of pain-free and
pain-relief episodes 2 and 24 h after frovatriptan intake for
the 73 attacks related to and for the 156 attacks unrelated to
the menstrual cycle. Frequency of pain relief at 2 and 24 h
was 52 and 83% in menstrually related attacks and 63 and
90% in non-menstrually related attacks, with no statisti-
cally signiﬁcant difference between the two type of
migraine (p = NS). Similarly, the rate of pain-free epi-
sodes at 2 and 24 h was 22 and 74% in MRM and 28 and
81% in non-MRM (p = NS).
Discussion
In this analysis acute treatment of MRM with frovatriptan
and zolmitriptan resulted in similar proportions of pain-
relief episodes at 2 and 24 h and of pain-free episodes at 2
and 24 h, indicating a superimposable efﬁcacy of the two
triptans. However, as respect to zolmitriptan, frovatriptan
showed lower rates of headache recurrence over the 24 h.
Table 1 Results for the comparison of study endpoints between the
two treatment groups
Frovatriptan Zolmitriptan p
Pain-relief episodes at 2 h 31 (52) 26 (53) NS
Pain-free episodes at 2 h 16 (22) 17 (26) NS
Pain-relief episodes at 24 h 50 (83) 40 (82) NS
Pain-free episodes at 24 h 54 (74) 45 (69) NS
Recurrent episodes at 24 h 11 (15) 14 (22) \0.05
Data are reported as absolute (n) and relative (%) frequency. P refers
to the statistical signiﬁcance of the difference between the two study
drugs
Fig. 1 Cumulative hazard of recurrence over the 24 h during
treatment with frovatriptan (continuous line) or zolmitriptan (dashed
line) in the 76 women with MRM
Table 2 Pain-free episodes at 2 and 24 h according to baseline
headache intensity in the two treatment groups
Frovatriptan Zolmitriptan p
Pain-free episodes at 2 h
Mild 5 (31) 8 (47) NS
Moderate–severe 11 (69) 9 (53)
Pain-free episodes at 24 h
Mild 11 (20) 11 (24) NS
Moderate–severe 43 (80) 34 (76)
Data are reported as absolute (n) and relative (%) frequency. P refers
to the statistical signiﬁcance of the difference between the two study
drugs
Table 3 Pain-free and pain-relief episodes at 2 and 24 h in MRM
(n = 73) and non-MRM (n = 156) attacks treated with frovatriptan
MRM Non-MRM p
Pain-relief episodes at 2 h 31 (52) 82 (63) NS
Pain-free episodes at 2 h 16 (22) 43 (28) NS
Pain-relief episodes at 24 h 50 (83) 118 (90) NS
Pain-free episodes at 24 h 54 (74) 127 (81) NS
Data are reported as absolute (n) and relative (%) frequency. P refers
to the statistical signiﬁcance of the difference between the two types
of migraine attacks
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may be largely attributable to the different pharmacoki-
netics of the two compounds. Zolmitriptan has a slightly
shorter time to maximum concentration than frovatriptan
(1.5 h vs. 2–4 h), but frovatriptan has a longer half-life
than zolmitriptan (25–26 h vs. 3 h), which might explain
the same frequencies of pain-relief and pain-free episodes
with the two study drugs and why frovatriptan, unlike
zolmitriptan, greatly reduced the risk of migraine recur-
rence [31–33]. Interestingly, frovatriptan showed a similar
efﬁcacy in MRM and non-MRM episodes, this being par-
ticularly important since MRM attacks are usually longer
lasting, more severe and more difﬁcult to treat than non-
menstrually related ones.
This is the ﬁrst study proving the efﬁcacy of frovatriptan
as acute treatment of MRM. The ﬁnding adds to and
completes that of previous efﬁcacy studies of frovatriptan
as intermittent preventive therapy for menstrual migraine:
frovatriptan started 2 days before the expected onset of
headache and continued for 6 days, was always found
superior to placebo in reducing the frequency of menstrual
migraine. A randomized, double-blind, placebo controlled
study involving 410 women showed a headache incidence
of only 8% when frovatriptan was given at dosage of
2.5 mg twice-daily and of 31% when given once-daily,
while the incidence was 58% under placebo [26]. A post-
hoc analysis of a randomized, double-blind, placebo con-
trolled study in a population of 179 women experiencing
MRM showed a signiﬁcantly less prevalence of this con-
dition with frovatriptan 2.5 mg twice (38%) or once-daily
(51%) than with placebo (67%) [27]. These latter results
are in line with those of a previous randomized, double-
blind, placebo-controlled study of the same authors carried
out in 546 women migraineurs [28].
As regards zolmitriptan, some evidence as acute treat-
ment of menstrual migraine is available from the literature
and thus a comparison may be inferred from previous
studies. In published studies pain relief at 2 h with
zolmitriptan ranged between 48 and 69% [13–15], pain free
at 2 h between 28 and 41% [13, 14] and recurrence at 24 h
between 29 and 35% [13, 14]: in our study the corre-
sponding ﬁgures for zolmitriptan were very similar with
respect to pain relief at 2 h (53%) and slightly lower for
pain free at 2 h (26%) and recurrence at 24 h (22%). These
differences might be attributed to differences in study
design, patients’ characteristics and dose of zolmitriptan
employed.
This is also the ﬁrst direct comparison study between
frovatriptan and another triptan in MRM. Our study and a
comparison study between almotriptan and zolmitriptan
[14] are the only two available head-to-head double-blind,
randomized studies comparing the efﬁcacy of two triptans
in MRM. Though both studies share the limitations of
post-hoc analysis, they are useful because no such pro-
spective studies on triptans in menstrual migraine have yet
been carried out. Limitations of our study are at least
partially contrasted by the large number of subjects inclu-
ded in the analysis, approximating two-third of those of the
main study. In addition, baseline characteristic of our
subgroup of migraineurs were quite similar to those of the
main study population and the results for the efﬁcacy
endpoints explored and for frovatriptan were not different
for MRM and non-MRM attacks [29]. We also limited as
much as possible the number of endpoints and analyses,
and the study assumptions, considering this subgroup
analysis as a starting point for subsequent clinical trials to
conﬁrm or refute the ﬁnding, rather than being viewed as a
deﬁnitive result.
Thus, the good sustained relief shown by frovatriptan in
our study, seems to support indication of frovatriptan not
only, as previously suggested, for preventive treatment of
MRM [24], but also for managing the acute attack. Though
frovatriptan and zolmitriptan showed a similar efﬁcacy in
the immediate, the sustained analgesic effect of frovatrip-
tan supported by a lesser risk of recurrence makes this drug
the best choice for those patients with long-duration or
recurrent migraine attacks [34, 35].
Conclusions
Our analysis of data from a multicenter, randomized, dou-
ble-blind, head-to-head study suggests that frovatriptan and
zolmitriptan are similarly effective in the immediate treat-
ment of women with MRM. The study provides the ﬁrst
evidence that frovatriptan is superior to zolmitriptan in
reducingrecurrenceinmenstrualmigrainepatients,showing
a better sustained relief.
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